What МОРЕЛОР КСИЛО Treats: Main Uses and Benefits

This medicine is commonly used as a nasal decongestant for the temporary relief of nasal congestion associated with various conditions. It is relevant in conditions characterized by periods of heightened symptoms, including the common cold, seasonal allergic rhinitis (hay fever), and acute rhinosinusitis.

---

Symptomatic Relief and Functional Support

This medicine is applied across domains where additional symptomatic support is needed, and is relevant for easing the stuffy nose and nasal obstruction accompanying acute viral infections. It may assist with easing the congestion in the nasal passages, providing supportive relief that may help to ease the overall symptom load of breathing difficulties. The medication is relevant when symptoms create noticeable physiological strain or interfere with daily comfort.

“The medication is generally applied when congestion disrupts stability and temporary assistance is needed.”

This functional relief is generally considered relevant when symptoms create noticeable interference with daily activities or disrupt sleep, and may help patients cope more steadily with symptom fluctuations, contributing to improved comfort during periods of heightened symptoms.

---

Quick Fact: Supports Management of Nasal Obstruction The medication is applied to address symptom clusters that interfere with daily comfort, such as a blocked nose and difficulty with nasal airflow. It contributes to improved comfort during episodes of heightened discomfort by assisting with functional stability.

Regulatory References

1. DailyMed (NIH) overview

The eligibility for using МОРЕЛОР КСИЛО is determined by official regulatory documents based on age, pre-existing conditions, and physiological status.

Contraindicated Populations (Must Not Use)

Use is absolutely contraindicated in infants and young children under the age of two years. The medicine must not be used by individuals with Hypersensitivity to Xylometazoline, Narrow-Angle Glaucoma, Rhinitis Sicca, or severe uncontrolled hypertension and cardiovascular disorders. Use is also strictly prohibited in patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of cessation, due to the risk associated with its sympathomimetic action.

Restricted and Approved Eligibility

Adults and Adolescents (12 years and over) are the population eligible for the standard 0.1% concentration. Children aged 2 to 11 years are restricted to the 0.05% strength solution. Caution is officially advised for patients with coexisting conditions, including diabetes mellitus, hyperthyroidism, prostatic hypertrophy, and Long QT Syndrome. Regarding physiological status, use is officially not recommended during pregnancy as a precaution, and breastfeeding requires professional medical advice.

Interactions with other medicines and products

This section outlines the officially documented interaction profile of МОРЕЛОР КСИЛО (Xylometazoline), based strictly on government regulatory documents.

Property	Value
Interacting Product Categories	Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants, Other Sympathomimetic Agents.
Mechanistic Basis	Pharmacodynamic (Potentiation of Pressor Effects / Enhanced Hypertensive Effect).
Timing-Separation Rule	Do not use during MAOI treatment and for a period of two weeks after stopping an MAOI.

Interaction Classifications and Restrictions

The most significant documented interaction is the combination with Monoamine Oxidase Inhibitors (MAOIs), which is formally classified as contraindicated by regulatory authorities. This restriction is enforced due to the severe risk of potentiating a hypertensive crisis (a sharp, dangerous increase in blood pressure). The regulatory instruction specifies a mandatory two-week washout period between discontinuing an MAOI and starting Xylometazoline to mitigate this risk.

Furthermore, the official product labeling indicates that concomitant use with Tricyclic or Tetracyclic Antidepressants may enhance the drug's pressor effects. Caution is also advised regarding the co-administration of Xylometazoline with Other Sympathomimetic Agents, as this may lead to an additive increase in cardiovascular stimulation.

alpha-Adrenergic Receptor Agonism and Local Vasoconstriction

The primary mechanism of МОРЕЛОР КСИЛО involves acting as a direct-acting agonist on the alpha1 adrenergic receptors present on the vascular smooth muscle in the nasal lining. This highly specific molecular interaction initiates a signal cascade that causes the small blood vessels to contract forcefully, a process known as vasoconstriction.

---

Regulation of Nasal Tissue Volume and Airflow

The resulting vasoconstriction physically reduces the volume of blood flowing through the nasal mucosa. This decrease in local blood volume is the key physiological step that attenuates the tissue edema (swelling) and hyperemia (excessive blood engorgement). By shrinking the swollen tissue, the mechanism induces a change in tissue volume, increasing the internal diameter of the nasal passages, which is a physiological consequence of the localized vascular modulation.

---

Constraints of Sustained Receptor Activation

The mechanism is biologically constrained by receptor adaptation: prolonged and excessive use leads to progressive receptor desensitization (tachyphylaxis), reducing the magnitude of the vasoconstrictive effect. This functional exhaustion of the alpha1 receptors is the mechanistic basis for the subsequent development of rhinitis medicamentosa upon cessation of administration.

Official Administration Guidelines

The administration of МОРЕЛОР КСИЛО (Xylometazoline) is restricted to topical nasal use only. The instruction set defines the appropriate concentration, dose, frequency, and maximum duration, which are standardized to ensure proper application.

Concentration and Dosing

The medicine is offered in two concentrations, with the appropriate strength tied directly to the user's age. The 0.1% concentration is designated for use by adults and adolescents 12 years of age and older, typically administered as 2 or 3 sprays in each nostril. For children between 2 and 11 years, the 0.05% concentration is used at a lower, age-appropriate dose. Use is generally not recommended in children under 2 years of age.

Frequency and Duration Constraints

Usage is intended to be short-term. Dosing frequency is controlled, with the medicine not administered more often than three times daily, maintaining a minimum interval of 8 to 10 hours between applications. Guidelines specify that the course of treatment should not exceed 3 to 7 consecutive days.

Procedural Requirements

Before the initial use of a new spray device, it is necessary to prime the pump until a uniform mist is released. It is also a standard procedural instruction to clear the nose gently before administering the product. The final application of the day is often recommended to be taken shortly before retiring to bed. This protocol ensures precise, time-controlled application within the specified parameters.

Research evidence / Overview of studies for МОРЕЛОР КСИЛО

Evidence for Short-Term Relief of Acute Nasal Congestion

Research has primarily focused on the medicine's short-term evaluation for conditions characterized by episodic or acute changes in the nasal passages, such as the common cold or acute rhinitis. Studies conducted during periods of increased symptom activity primarily used short-term, placebo-controlled Randomized Controlled Trials (RCTs) to explore outcomes related to acute symptom changes. These studies were used in research exploring how symptoms change over time by monitoring two main types of outcomes: objective nasal airflow (measured by specialized instruments) and patient-reported outcomes describing perceived discomfort.

In these research scenarios, studies monitored changes in both physical airflow and how subjects reported their experiences with nasal obstruction. Research explores measured changes in nasal conductance observed during the study period, with assessments typically conducted hourly over the short-term. Findings describe patterns observed in the studies, and studies monitored timepoints related to how these changes were measured and the overall duration over which these changes were observed.

Research in Specific Clinical Contexts

Research has also explored the substance in specific clinical settings, particularly in studies focusing on episodes where symptoms become more noticeable after nasal procedures. For instance, research examined the substance in studies conducted on adult populations recovering from nasal surgery, such as septoplasty.

These trials were used in research exploring how symptoms change over time by focusing on outcomes related to physical discomfort in the immediate recovery phase. Specifically, research examined outcomes linked to inflammatory or irritative states, such as measuring postoperative clinical findings like edema (swelling) and crusting in the nasal passages.

What Remains Unclear and Evidence Gaps

The evidence contributes to the broader evidence landscape by highlighting what is known—and what is still uncertain. Certainty remains low in several areas, largely due to the nature of the condition and the short-term design of the trials. Long-term effects are not fully established because the follow-up durations were limited across most studies, providing limited information for long-term outcomes or how symptom patterns might evolve over extended durations. Data for certain groups, such as those with specific comorbidities, remain insufficient.

Key Studies & References

1. Label: SINOSIL NASAL DECONGESTANT- xylometazoline hcl spray - DailyMed (FDA Regulatory Information)

Common questions about МОРЕЛОР КСИЛО (FAQ)

Q: How should I store Drug X?

According to the official product information, Drug X should be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). To ensure the medication remains effective, it should be protected from moisture and light. The medication should remain in its original container.

Q: Can I drink alcohol while taking Drug X?

Official labeling for Drug X indicates that taking this medicine with alcohol may increase the risk of specific side effects, such as dizziness or central nervous system (CNS) depression. This combination may lead to increased drowsiness or impairment. Questions about alcohol consumption should be addressed with a healthcare professional.

Q: Does Drug X make you sleepy or affect driving?

Regulatory documents state that Drug X has been reported to cause CNS effects like dizziness or somnolence (sleepiness). Official labeling advises caution regarding the operation of hazardous machinery, including driving a car, until a person is aware of how the medication affects them. Activities requiring mental alertness should only be resumed when individuals are reasonably certain that Drug X does not negatively affect their ability.

Q: Is Drug X safe to take during pregnancy?

Official information indicates that limited data are available regarding the use of Drug X in pregnant women. Based on available information, the labeling advises that the medication be used during pregnancy only if the potential benefit is considered to outweigh any potential risk to the fetus. A healthcare provider can review this information to help determine the appropriate course of action.

Q: When should I NOT take Drug X (contraindications)?

Drug X is contraindicated, meaning its use is not recommended, in specific patient groups according to the official product information. This includes patients with a known hypersensitivity (severe allergic reaction) to the active substance or any of the inactive ingredients (excipients). It is also contraindicated in patients with certain pre-existing medical conditions, such as severe liver problems.

Q: What happens if I miss a dose of Drug X?

Regulatory patient information generally addresses missed doses by stating that if a dose is missed, it should be taken as soon as possible, unless it is close to the next scheduled dose. If a dose is missed, the goal is to return to the regular dosing schedule and avoid taking two doses simultaneously to compensate for a missed dose.

Official Storage and Disposal Requirements

Storage and disposal of МОРЕЛОР КСИЛО (Xylometazoline Nasal Solution) must strictly adhere to the conditions documented in official regulatory labeling.

Condition	Requirement
Temperature	Store below 25 C (77 F), or as specified by the local label. Avoid freezing.
Protection	Keep the product in its original package, tightly closed, and protect from light.
Stability	After first opening, the medicine must be used within a limited time, typically 28 or 60 days, and then the remainder must be discarded.
Child Safety	Mandatory to keep the solution out of the sight and reach of children.

Disposal

Do not dispose of this medicine by throwing it into household waste or flushing it down the toilet or sink. Unused or expired product must be managed in accordance with local regulatory pharmaceutical waste requirements.